Future-Proofed Pandemic Treatments and Protecting the Immunocompromised Population
Eugene Chan, MD, MPH, is the chairman and co-founder of Abpro, a company working to advance monoclonal antibodies to be used to treat Covid-19. He joins Neal to discuss the importance of protecting the immunocompromised population amidst mutating Covid-19 variants and shares the latest on the development of Abpro’s infectious disease antibody treatment that has demonstrated best-in-class efficacy against the multiple Omicron variants. For more information, visit: www.abpro.com.
Dr. Eugene Chan is a physician-inventor. He is currently Chairman, Co-Founder of Abpro, CEO of rHEALTH, and President, CSO of DNA Medicine Institute, a medical innovation laboratory. He has been honored as Esquire magazine’s Best and Brightest, one of MIT Technology Review’s Top 100 Innovators, and an XPRIZE winner. His work has contributed to the birth of next-generation sequencing, health monitoring in remote environments, and therapeutics. Dr. Chan holds over 60 patents and publications, with work funded by the NIH, NASA, and USAF. Dr. Chan received an A.B. in Biochemical Sciences from Harvard College summa cum laude in 1996, received an M.D. from Harvard Medical School with honors in 2007, and trained in medicine at the Brigham and Women’s Hospital.
